Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables: 2010-2025

Historic Change in Receivables for Heron Therapeutics (HRTX) over the last 10 years, with Sep 2025 value amounting to $1.1 million.

  • Heron Therapeutics' Change in Receivables rose 116.73% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 331.81%. This contributed to the annual value of $18.7 million for FY2024, which is 131.75% up from last year.
  • Heron Therapeutics' Change in Receivables amounted to $1.1 million in Q3 2025, which was down 6.61% from $1.2 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Change in Receivables high stood at $25.2 million for Q2 2023, and its period low was -$12.9 million during Q3 2023.
  • Over the past 3 years, Heron Therapeutics' median Change in Receivables value was $1.1 million (recorded in 2025), while the average stood at $2.6 million.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Change in Receivables was 3,255.62% (2023), while the steepest drop was 784.24% (2023).
  • Quarterly analysis of 5 years shows Heron Therapeutics' Change in Receivables stood at -$7.6 million in 2021, then skyrocketed by 229.97% to $9.9 million in 2022, then slumped by 137.10% to -$3.7 million in 2023, then soared by 423.73% to $11.8 million in 2024, then surged by 116.73% to $1.1 million in 2025.
  • Its Change in Receivables stands at $1.1 million for Q3 2025, versus $1.2 million for Q2 2025 and -$145,000 for Q1 2025.